Kevin Nash's Contact Details

Kevin Nash's Company Details

Dharmacon

Portland, Oregon, United States • 201 - 500 Employees
Biotechnology

Dharmacon revolutionized the field of RNA synthesis in 1995 with the introduction of 2'-ACE synthesis chemistry and has been supporting the RNA and gene modulation research community for over 20 years. Dharmacon was an early participant in the RNA interference field and published key scientific contributions to the biological mechanism and research tool design and established market leadership with our siRNA platform. The acquisition of Open Biosystems strengthened our RNAi portfolio with genome-wide vector-based shRNA research tools.Today, our gene modulation research tools have expanded to include CRISPR-Cas9 gene editing reagents. We launched the very first synthetic CRISPR-Cas9 guide RNAs, and now offer one of the most comprehensive CRISPR gene editing portfolios in the industry, including the first arrayed synthetic CRISPR RNA whole human genome library. Our gene editing products include predesigned genome-wide lentiviral and synthetic guide RNA reagents designed by a validated algorithm, Cas9 nucleases, and design tools & kits for homology-directed repair. We have a well-established history of supporting the global genomics research community and we remain focused on the development and support of innovative, effective tools for the greater research community.